Sermorelin helps restore a healthy growth hormone rhythm, which supports natural testosterone levels , strength, and confidence
FDA Clears First Oral GLP-1 for Weight Loss On December 22, 2025, the FDA approved Novo Nordisks once-daily Wegovy pill (25 mg semaglutide), the first oral GLP-1 receptor agonist indicated for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight plus at least one weight-related comorbidity
The body produces GLP-1 in response to all kinds of food intake, but it has a very short duration of action because it is rapidly degraded by DPP-4 enzymes
Your healthcare team can provide training and address any concerns about injection technique or side effect management
Scientific Background Growth hormone secretion is regulated through complex endocrine pathways involving hypothalamic peptides and pituitary receptors
We understand the complex medical arguments required to prove pharmaceutical failure-to-warn claims and are actively investigating GLP-1 NAION eye stroke cases nationwide